France
Jean-Guillaume Lafay is an accomplished entrepreneur with extensive experience in biotech and investment. He is currently the Chairman and Founder of Norfoalk, a private equity company, and Dictamen, a charity fund. He is also a co-founder of several startups in the biotech sector, such as Allogenica founded in 2022 in cell therapy field, where he promotes science and innovation. In July 2024, he joined the Supervisory Board of Axoltis Pharma focusing on neurodegenerative diseases. Previously, Jean-Guillaume served as the CEO and Co-Founder of Mablink Bioscience from 2018 to 2023. Mablink, under his leadership, developed advanced Antibody Drug Conjugates (ADCs) using its proprietary PSARLink platform. The company achieved significant success and was acquired by Eli Lilly in December 2023, enhancing its ability to deliver transformative cancer therapies. Mablink’s technology, designed to precisely target cancer cells, has been recognized for its potential to address unmet medical needs in oncology. Jean-Guillaume’s career is distinguished by his people-centered approach and core values. He prioritizes the well-being and development of his employees, viewing them as central to the success of any entrepreneurial journey. His values revolve around integrity, trust, and a commitment to helping people. He believes in leveraging his expertise and partnerships to drive forward transformative therapies while ensuring that his teams are supported and empowered. This vision of combining cutting-edge science with a strong ethical foundation has been instrumental in his success and in the global impact of his ventures. Jean-Guillaume holds a Master’s degree in Organic Synthesis and Bioactive Molecules Chemistry from Université Claude Bernard Lyon 1. He is based in Lyon, France.
—-